The In vitro activity of BMY-28142 was compared with that of cefotaxime, ceftazidime, moxalactam, and imipenem against 639 clinical isolates and a number of in vitro-selected resistant mutants. BMY-28142 was the most potent compound against the members of the family Enterobacteriaceae with a MIC for 90% of the strains of 0.12 ,ug/ml. The activity against Pseudomonas aeruginosa was comparable to that of ceftazidime and imipenem. Strains of staphylococci were moderately susceptible to BMY-28142 (MIC required to inhibit 90% of strains, 4 ,ug/ml), but Streptococcus faecalis isolates were resistant. The activity of the five compounds was inoculum dependent for several gram-negative species. By a single-step selection procedure, resistant mutants were selected from strains of Citrobacter freundii, Enterobacter cloacae, and P. aeruginosa. The mutant frequencies with the cephalosporins, including BMY-28142, ranged between 10-6 and 10-8. BMY-28142 was the most active cephalosporin against these resistant organisms, most of them strong ,-lactamase producers. It inhibited all mutants of C. freundii and E. cloacae at 2 ,ug/ml and all mutants of P. aeruginosa at 32 ,ug/ml. Imipenem on the other hand was as active on all of these resistant organisms as on the parent strains. Fig. 1) , is a new extended-spectrum cephalosporin for parenteral use. The compound is structurally similar to cefotaxime but has a 1-methylpyrrolidine instead of the acetoxy group at position 3 of the dihydrothiazine ring.
acetamido]-3-(1-methylpyrrolidino)-methyl-3-cephem-4-carboxylate ( Fig. 1) , is a new extended-spectrum cephalosporin for parenteral use. The compound is structurally similar to cefotaxime but has a 1-methylpyrrolidine instead of the acetoxy group at position 3 of the dihydrothiazine ring.
The third-generation cephalosporins combine a highlactamase stability with a broad antibacterial spectrum and potent activities against gram-negative bacteria. However, their antibacterial activity against Pseudomonas aeruginosa is variable, and they are generally less active on gram-positive organisms than their first-generation counterparts. Moreover, several reports have shown the emergence in vitro and in vivo of resistant mutants at relatively high frequency (3, 7, 12) . Most involved strains belong to Enterobacter, Citrobacter, and Pseudomonas spp., genera producing inducible cephalosporinases which can be derepressed to constitutive synthesis.
The present study compares the in vitro activity of BMY-28142 with that of currently available third-generation cephalosporins and imipenem. Attention was paid to the rate of in vitro emergence of resistant mutants and the degree of cross-resistance of these mutants to the other compounds.
MATERIALS AND lands. They were identified by standard criteria (4) . In addition, a number of known resistant or P-lactamaseproducing strains from our culture collection were also included.
Susceptibility studies. MICs were determined by an agar dilution technique. Serial dilutions (ranging from 0.008 to 128 ,ug/ml) of freshly prepared antibiotic were made in Mueller-Hinton agar. This medium was supplemented with 5% defibrinated horse blood for fastidious streptococci. The organisms were grown overnight in tryptic soy broth or Todd-Hewitt broth (streptococci) and diluted to an inoculum density of 107 cells per ml. These suspensions were applied to the plates with the aid of a multipoint inoculator (Mast Laboratories), each pin of which delivered about 2 ,ul of liquid (104 cells per spot). The swarming of Proteus spp. was prevented by incorporating 60 ,ul of 1-(4-nitrophenyl)-1,2,3-propantriol per ml into the agar medium. The plates were incubated at 37°C for 18 h. For streptococci, incubation was carried out in an atmosphere of 5% CO2. The MIC was scored as the lowest concentration of antibiotic that prevented visible growth. The effect of inoculum size on the MIC of 10 strains each of several species was determined in the same way by using an inoculum that was 100-fold more concentrated.
Mutant selection. Of Citrobacter freundii, Enterobacter cloacae, and P. aeruginosa, three strains each were used for these studies. They were sensitive to carbenicillin and produced a low level of inducible cephalosporinase. Resist Table 3 ]. The ,-lactamase activity of these mutants was not substantially different from that of the parent organisms.
The cross-resistance to the other compounds of a number of representative mutant strains is shown in Table 3 . The resistance of these strains proved to be stable during several subcultures in the absence of antibiotic. Imipenem was found to be as active on the mutants as on the parent organisms. Among the cephalosporins, BMY-28142 was clearly the most active compound irrespective of the agent used for selection. It inhibited all mutants of Enterobacter cloacae and C. freundii at 2 ,ug/ml and all mutants of Pseudomonas aeruginosa at 32 ,ug/ml. DISCUSSION Recently, a number of new cephem antibiotics have been developed which display high intrinsic activity against the Enterobacteriaceae and enhanced antipseudomonal activity (2) . Although clinical trials have undoubtedly demonstrated the effectiveness of these compounds, there are several gaps in the activity profile of most of them (9) .
In the present study we found BMY-28142 to have some advantages over the third-generation cephalosporins, especially with respect to its gram-negative spectrum. It was the most potent compound against the Enterobacteriaceae, whereas its activity against Pseudomonas aeruginosa was not substantially different from that of ceftazidime and imipenem, which are currently known as the most potent 3-lactam compounds against this species (11) . The antistaphylococcal activity of BMY-28142 was most similar to that of cefotaxime but remains below that reported for older cephalosporins (5 (3, 7, 12) and is most probably due to the derepression of the inducible cephalosporinase to constitutive synthesis (8) . The overproduced P-lactamase then acts by hydrolyzing the cephalosporins or by merely trapping them, thereby creating an enzymatic penetrability barrier (13) . All the cephalosporins, including BMY-28142, were able to elicit P-lactamasepositive mutants at a readily detectable frequency. Although these mutants were less susceptible to BMY-28142 than the parent strains, the compound inhibited all of them at concentrations which would be readily achievable in vivo. Imipenem on the other hand proved to be the only compound with equal activity against parent and mutant strains and thus seemed to be unaffected by the derepression of chromosomal P-lactamases, a statement also made by Sanders (6). The mechanisms which make some ,-lactam antibiotics partially or completely refractory to the effect of induction or derepression of these enzymes remains to be established.
The results of this study indicate that BMY-28142 could be a useful agent for the treatment of serious infections, notably when resistant organisms or bacteria with inducible enzymes are involved. Further studies on in vivo activity and pharmacokinetic and toxicological behavior are therefore warranted.
